AMENDMENTS TO THE CLAIMS

1. (Currently amended) An isolated nucleic acid molecule comprising the ~~cDNA represented as a~~ nucleotide sequence of SEQ ID NO:2~~, which codes for Saxatilin, a protein derived from venom of Agkistrodon saxatilis emelianov~~.

2. (Currently amended) An isolated polypeptide comprising the ~~Saxatilin represented as an~~ amino acid sequence of SEQ ID NO:1 ~~which is derived from the cDNA of claim 1~~.

3. (Currently amended) A process for preparing ~~Saxatilin~~ a polypeptide comprising the amino acid sequence of SEQ ID NO:1 ~~which comprises~~ comprising the steps of:

(i) gel filtration of venom collected from Agkistrodon saxatilis emelianov to obtain an active fraction having an inhibitory effect on platelet aggregation; and,

(ii) applying the active fraction to high performance liquid chromatography to purify ~~Saxatilin~~ a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

4. (Currently amended) An expression vector ~~pPSAX containing~~ comprising the ~~cDNA~~ nucleic acid molecule of claim 1.

5. (Currently amended) A biologically pure culture of Pichia pastoris Y/pPSAX (KCCM-10201) which is obtained by transforming the expression vector ~~pPSAX~~ of claim 4 into Pichia pastoris GS115.

6. (Currently amended) A process for preparing a recombinant ~~Saxatilin~~ polypeptide comprising the amino acid sequence of SEQ ID NO:1 which comprises a step of culturing a microorganism transformed with an expression vector containing the ~~cDNA~~ nucleic acid molecule

of claim 1 to obtain a recombinant ~~Saxatilin~~ polypeptide comprising the amino acid sequence of SEQ ID NO:1.

7. (Currently amended) The process for preparing the recombinant ~~Saxatilin~~ polypeptide of claim 6, wherein the expression vector is pPSAX.

8. (Currently amended) The process for preparing the recombinant ~~Saxatilin~~ polypeptide of claim 6, wherein the transformed microorganism is Pichia pastoris Y/pPSAX (KCCM-10201).

9. (Currently amended) The process for preparing the recombinant ~~Saxatilin~~ polypeptide of claim 8, wherein the transformed microorganism is cultured under [[a]] conditions of pH 5.5 to 6.5, 25°C to 35°C for 12 to 24 hours, harvested by centrifugation and cultured again [[on]] in a medium containing 0.5% to 1.5% (v/v) methanol under [[a]] conditions of pH 5.5 to 6.5, 25°C to 35°C for 72 to 120 hours.

10. (Currently amended) The process for preparing the recombinant ~~Saxatilin~~ polypeptide of claim 8, wherein [[the]] supernatant from a culture containing the transformed microorganism is collected and subjected to a hydrophobic column and high performance liquid chromatography ~~to purify Saxatilin~~.

11. (Currently amended) A pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:1 ~~Anti-platelet agent comprising an active ingredient of Saxatilin~~ and a pharmaceutically acceptable carrier.

12. (Currently amended) The pharmaceutical composition of claim 11, wherein said composition is an [[Anti]] anti-tumor agent ~~comprising an active ingredient of Saxatilin and pharmaceutically acceptable carrier~~.

13. (New) The pharmaceutical composition of claim 11, wherein said composition is an anti-platelet aggregation agent.